Whitehawk Therapeutics Inc
NASDAQ:WHWKBiotechnology
+$0.06 today
- Market cap
- $184.70M
- Beta
- 0.77
- P/E (TTM)
- -2.6
- EPS (TTM)
- -$1.67
Volume 0.28M
Average 0.31M
WHWK Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Whitehawk Therapeutics IncNASDAQ: WHWK
Research & Development · Q1 FY2026 · quarter ended Mar 2026
Research & development grows, but more slowly than its trailing trend
Q1 FY2026 research & development of $17.23M rose 96.1% year over year, behind the +115.1% change in trailing-twelve-month research & development. Sequentially, it fell 9.4% from the prior quarter. Over 3 fiscal years it compounded at +40.7% a year.
Context
- Research & development amounted to 1273.1% of revenue in FY2025, up 1076.7 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +96.1% toward the trailing-twelve-month pace of +115.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 90.96M USD
- Year-over-year change
- +78.3%
- 4-year CAGR
- +46.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 90.96M | +78.3% |
| FY2024 | 2024-12-31 | 51.03M | +4.3% |
| FY2023 | 2023-12-31 | 48.93M | +49.8% |
| FY2022 | 2022-12-31 | 32.66M | +66.0% |
| FY2021 | 2021-12-31 | 19.67M | — |
Research & Development vs competitors
How WHWK compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +115.1% is the highest of 9, against a peer median of -13.4%.
- Over three fiscal years its annual growth of +40.7% compares with a peer median of +2.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $135.36M USD | -19.9% | -12.2% | 86.2% | |
| LTM Mar 2026 | $108.76M USD | -25.2% | -14.7% | — | |
WHWKWhitehawk Therapeutics Inc | LTM Mar 2026 | $99.41M USD | +115.1% | +40.7% | — |
| LTM Mar 2026 | $79.04M USD | -54.8% | +4.0% | — | |
| LTM Mar 2026 | $35.41M USD | +46.4% | +65.0% | — | |
| LTM Mar 2026 | $30.07M USD | -8.9% | +1.3% | 422.2% | |
| LTM Mar 2026 | $20.26M USD | +102.3% | +57.1% | — | |
| LTM Mar 2026 | CA$19.63M CAD | +4.7% | +15.5% | — | |
| LTM Mar 2026 | $12.86M USD | -17.9% | -24.0% | 9596.3% | |
| Peer median (excluding WHWK) | — | -13.4% | +2.7% | 422.2% | |
Competitors are the stored peer set for WHWK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 1.12M | 15.22M | 24.35M | 25.98M | 7.15M |
| Cost of Revenue | 19.67M | 34M | 51.74M | 54.05M | 760K |
| Gross Profit | (18.55M) | (18.78M) | (27.38M) | (28.07M) | 6.39M |
| Gross Margin | -1656.3% | -123.4% | -112.4% | -108.0% | 89.4% |
| Research & Development | 19.67M | 32.66M | 48.93M | 51.03M | 90.96M |
| Selling, General & Admin | 18.51M | 40.18M | 44.55M | 36.75M | 29.82M |
| Operating Expenses | 92.67M | 43.9M | 44.55M | 39.39M | 120.79M |
| Depreciation & Amortization | 105K | 159K | 169K | 193K | 79K |
| EBITDA | (36.96M) | (58.8M) | (65.37M) | (64.63M) | (20.52M) |
| EBITDA Margin | -3299.6% | -386.4% | -268.4% | -248.7% | -287.2% |
| Operating Income | (111.22M) | (62.68M) | (71.93M) | (67.46M) | (114.4M) |
| Operating Margin | -9930.1% | -411.9% | -295.4% | -259.6% | -1601.1% |
| Interest Income | 13K | 2.4M | 6.4M | 3.93M | 6.23M |
| Interest Expense | 665K | 230K | 231K | 154K | 0 |
| Other Income / Expenses | 1.13M | 2.17M | 6.17M | 3.77M | 93.8M |
| Income Before Tax | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Pre-Tax Margin | -9829.3% | -397.7% | -270.0% | -245.1% | -288.3% |
| Income Tax Expense | 2K | 0 | 0 | 0 | 0 |
| Net Income | (110.09M) | (60.51M) | (65.77M) | (63.69M) | (20.6M) |
| Net Margin | -9829.5% | -397.7% | -270.0% | -245.1% | -288.3% |
| EPS (Basic) | (12.41) | (2.69) | (2.44) | (2.36) | (0.33) |
| EPS (Diluted) | (12.41) | (2.69) | (2.44) | (2.36) | (0.33) |
| Weighted Avg Shares | 8.87M | 22.51M | 26.92M | 27.03M | 61.89M |
| Weighted Avg Shares (Diluted) | 8.92M | 22.51M | 26.92M | 27.03M | 61.89M |
Whitehawk Therapeutics Inc
NASDAQ:WHWK
Intrinsic Alpha fair value
Locked
Current Price
$3.13
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.